Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fludarabine + cytarabine + idarubicin
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of fludarabine, cytarabine, and idarubicin. It is primarily used in the treatment of acute myeloid leukemia (AML), particularly for relapsed/refractory cases or as induction therapy in newly diagnosed patients with high-risk features. Fludarabine and cytarabine are antimetabolite chemotherapeutic agents that inhibit DNA synthesis by interfering with DNA replication and repair, leading to cell death in rapidly dividing cells. Idarubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, resulting in inhibition of DNA replication and repair as well as generation of free radicals that cause further cellular damage. The combination exploits synergistic effects to maximize anti-leukemic activity[1][3][5]. This regimen may be referred to as FLA-IDA or m-FLAI (modified dosing) depending on the protocol.
- Other names
- FLA-IDAm-FLAI
02
Targets
TOP2A (DNA topoisomerase II)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on fludarabine + cytarabine + idarubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fludarabine + cytarabine + idarubicin.